Alkermes reviews $42.3 million revenue for first-quarter fiscal 2011 Alkermes, Inc cialis bivirkninger . today reported financial results for its first quarter of fiscal 2011, which ended on June 30, 2010. Worldwide product sales of RISPERDAL CONSTA by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. And Janssen-Cilag were approximately $356 million, a rise of 3.4 % on an operational basis year-over-year, and so are based on revenue in more than 70 countries. GAAP net loss of $13.4 million and pro forma net loss of $9.0 million. Strong financial position, with money and total investments of $328.5 million, ahead of redemption of all remaining non-recourse RISPERDAL CONSTA secured 7 percent Notes on July 1, 2010, at a complete cost of around $46.4 million.
Alimera Sciences, Inc. Individuals in the trials were randomized to get either high dose ILUVIEN, low dosage ILUVIEN or control treatment. Alimera previously provided data for both the low and high dosage patient results at month 24. Predicated on these data, Alimera submitted a fresh Drug Software on June 29, 2010 for approval of only the low dose. Therefore, only the reduced dose data is discussed and presented in this release. Data through month 36 for the entire Analysis Set in Trial A demonstrated statistically significant therapeutic ramifications of 28.9 percent at month 30. Results from Trial B had been similar. In comparison, at month 24 in Trial A, 26.8 percent of ILUVIEN sufferers and 14.7 percent of control patients had gained 15 or even more letters.